story of the week
Adaptive Dosing of Nivolumab Plus Ipilimumab in Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study)
J. Clin. Oncol 2022 Apr 01;40(10)1059-1067, MA Postow, DA Goldman, AN Shoushtari, A Betof Warner, MK Callahan, P Momtaz, JW Smithy, E Naito, MK Cugliari, V Raber, O Eton, SG Nair, KS Panageas, JD Wolchok, PB ChapmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.